newsfilter
← Latest News
Business Wire·

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient